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Abstract
Introduction: The implementation of lifelong antiretroviral treatment (ART) for all pregnant women (Option B) in Malawi has
resulted in a significant increase in the number of HIV-positive pregnant women initiating treatment. However, research has
highlighted the challenge of retaining newly initiated women in care. This study explores barriers and facilitators that affect a
woman’s decision to initiate and to adhere to Option B.
Methods: A total of 39 in-depth interviews and 16 focus group discussions were conducted. Eligible women were ]18 years
old, living with HIV and either pregnant and receiving antenatal care from a study site or had delivered a child within the last
18 months, breastfed their child and received services at one of the study sites. Eligible women were identified by healthcare
workers (HCWs) in the antenatal clinic and ART unit. Focus groups were also conducted with HCWs employed in these
departments. Qualitative data were analyzed using Maxqda version 10 (VERBI Software, Berlin, Germany).
Results: The general perception towards the drug regimen used in Option B was positive; women reported fewer side effects
and acknowledged the positive benefits of ART. Women felt hopeful about prolonging their life and having an HIV-uninfected
baby, yet grappled with the fact that ART is a lifelong commitment. Women and HCWs discussed challenges with the counselling
services for prevention of mother-to-child HIV transmission under the new Option B guidelines, and many women struggled
with initiating ART on the same day as learning their HIV status. Women wanted to discuss their circumstances with their
husbands first, receive a CD4 count and obtain an HIV test at another facility to confirm their HIV status. HCWs expressed
concern that women might just agree to take the drugs to please them. HCWs also discussed concerns around loss to follow-up
and drug resistance.
Conclusions: Although Option B has significantly increased the number of women initiating ART, there are still challenges that
need to be addressed to strengthen initiation, adherence and retention in care. Strategies to strengthen the counselling services
upon diagnosis need to be developed to improve same-day initiation of ART and long-term adherence.
Keywords: Option B; lifelong HIV treatment; counselling; same-day initiation; prevention of mother-to-child transmission of
HIV; qualitative.
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Introduction
Prevention of mother-to-child transmission (PMTCT) involves
a cascade of services provided to HIV-positive women in-
cluding antenatal services and HIV testing during pregnancy,
use of antiretroviral treatment (ART), safe childbirth prac-
tices, appropriate infant feeding and testing the child for
HIV. In July 2011, Malawi initiated Option B, an adaptation
of the WHO 2010 PMTCT guidelines [1]. Under this new
approach, all HIV-positive pregnant and breastfeeding women
initiate ART for life, irrespective of their CD4 count or clinical
staging (Table 1). Option B services were decentralized to
primary care facilities and integrated with maternal and child
health (MCH) services, and nurses were trained to initiate
women on ART [2].
Another shift in ART initiation in Malawi under the Option
B guidelines was to initiate women on ART the same day
they receive their HIV-positive diagnosis. Before receiving
their first supply of ART, women receive general group coun-
selling, followed by individual counselling. Women receive
monthly adherence counselling for the next six months
followed by a general adherence counselling session to
transition to three-month follow-up visits. Targeted counsel-
ling is provided any time a provider notices that there are
adherence challenges. Initiating all women on lifelong ART the
same day they learn their HIV status resulted in a sevenfold
increase in the number of pregnant and breastfeeding women
starting ART, from 1257 in the second quarter of 2011 to
10,663 in the third quarter of 2012 [3].
Despite the increased number of pregnant women initiated
on ART, there have been challenges with the roll-out of Option
B in Malawi. A study on retention in care in Malawi showed
that six months after ART initiation, the proportion of Option
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B patients who had had no follow-up visit after ART
initiation or who were lost to follow-up (LTFU) was 23.9%
(95% CI: 22.6 to 25.3%) [4]. The same study reported that
Option B patients who started ART while pregnant were
five times more likely to fail to return to the clinics after the
initial visit compared to patients who started ART for their
own health. Previous research on Option B in Malawi cited
transportation barriers, not understanding the initial ART
counselling session and ART side effects as some of the main
reasons women do not return to the facility [5]. However, the
majority of research on Option B has been quantitative, not
allowing for in-depth exploration of women’s perspectives
towards Option B.
More knowledge is needed about what shapes acceptance
of and adherence to ART among women initiating ART
during pregnancy. An exploration of these questions has
been identified as a priority in Malawi and elsewhere [6]. In
particular, there is an urgent need to understand why a large
proportion of women enrolled in the Option B programme
do not return after the initial visit. Therefore, this study was
designed to explore the critical issues shaping acceptance to




This qualitative study used in-depth interviews (IDIs) and
focus group discussions (FGDs) to explore the experiences
and perceptions of pregnant and postpartum HIV-positive
women enrolled in Option B, and FGDs to explore the
perspectives of healthcare workers (HCWs). Study partici-
pants only participated in either an IDI or an FGD, but not
both; data were only collected at one time point.
Site selection
To gain perspectives from the different types of settings,
data were collected from Likuni Mission Hospital (urban),
Kabadula Community Hospital (rural) and Dedza and Mchinji
District Hospitals (both peri-urban). Sites were selected that
were either government-owned (free services) or private
(pay for services) to gain perspectives from both types of
Table 1. Differences in PMTCT before and after Option B in Malawi
Before Option B After Option B
CD4 test CD4 count test was required. No CD4 count test required.
Initiation of ART Lifelong ART only initiated if woman had a CD4
count B350 cells/mL.
Initiate women on lifelong ART regardless of CD4
count.
Time to initiation of ART from learning
HIV status
Women initiated within 2 to 6 weeks of learning
HIV status.
Women initiated on the same day they learn their
HIV status.
Number of counselling sessions received
before initiating ART
ART was initiated at the third counselling session. Initiate ART at the first counselling session.
Drug regimen for ART-ineligible women AZT during pregnancy; AZT/3TC and single dose
NVP at delivery.
TDF/3TC/EFV.
Drug regimen for ART-eligible women AZT/3TC/NVP during pregnancy and delivery. TDF/3TC/EFV.
Frequency of medication Medicine taken twice a day. Medicine taken once a day.
‘‘Treatment supporter’’ requirement Women required to have a treatment supporter
present when initiating ART.
No treatment supporter required.
Where initiation occurs Possible to initiate in ART clinic only. Can initiate in ANC, ART, MCH and labour and
delivery.
Postpartum management Women with CD4 B350 cells/mL continued
lifelong ART; women with CD4 count ]350 cells/
mL received AZT/3TC for seven days after delivery.
Lifelong ART is continued in all women regardless
of CD4 cell count.
Infant antiretroviral prophylaxis Mother received AZT: Single-dose NVP plus AZT for
seven days to four weeks after birth (depending
on whether maternal AZT was given for at least
four weeks or less than four weeks antepartum).
Mother received ART: AZT for seven days.
NVP for six weeks after birth.
Breastfeeding guidance Women told to exclusively breastfeed for six
months and then stop breastfeeding.*
Women encouraged to exclusively breastfeed for
six months and then introduce complementary
feedings along with continued breastfeeding for
up to two years postpartum.*
*The change in breastfeeding guidelines was not part of Option B; however, the shift in breastfeeding recommendations in Malawi occurred
at the same time as Option B. ANC, antenatal clinic; ART, antiretroviral therapy; AZT, zidovudine; 3TC, lamivudine; MCH, maternal child health
clinic; NVP, nevirapine; PMTCT, prevention of mother-to-child transmission; TDF, tenofovir.
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sites. Within these parameters, the sites with the highest
volume of HIV-positive pregnant women were selected.
Data collection
Data were collected between September and December 2013
by trained research assistants (RAs) using semi-structured
interviews (IDIs) and FGDs that were audio-recorded. The
interview and topic guides included questions about knowl-
edge of HIV/AIDS, perceived risks and benefits of lifelong ART,
community perceptions about HIV and ART, and perceptions
and experiences related to the ability of the health facility to
provide the needed services. The interviews were conducted
by one RA while the FGD was conducted by two RAs; one
moderated, while the other observed and took notes. On
average, interviews took 60 minutes and FGDs lasted 130
minutes. Both IDIs and FGDs were conducted in the local
language of Chichewa by native speakers.
Eligible women were 18 years of age or older, living with
HIV and either a) pregnant and receiving antenatal care (ANC)
from a study site or b) had delivered a live child within the
last 18 months who was still alive, breastfed their child and
received services at one of study sites. Only women who
initiated the drug regimen associated with Option B
(tenofovir/lamivudine/efavirenz) within the recent pregnancy
were included. For some of the women, this was their first
experience with HIV medication, while other women had
been enrolled in a PMTCT programme during previous
pregnancies but were not currently receiving ART at entrance
into ANC.
HCWs providing services in the ANC and ART units were
trained on eligibility and would refer eligible women to the
RAs on site. To determine if a woman was on Option B,
HCWs would verify that they were receiving the drug
regimen associated with Option B. Once the RAs confirmed
eligibility, they would obtain informed consent and either
conduct an IDI or invite the women to return on a set day for
a FGD. Women who arrived earlier in the day were offered
participation in the IDI and those who arrived later were
invited to return for the FGD. Late arrival at the facility did
not allow women time to participate in an IDI and obtain
public transport home.
The only eligibility requirement for HCWs was to have
worked in the ANC or ART departments of the selected
facilities for the previous six months. HCWs were identified
and referred to the RAs by the nurse in charge. RAs
confirmed eligibility and invited eligible HCWs to participate
in a FGD on a set day. All eligible HCWs were invited to
participate, and this number never exceeded 12 HCWs within
any health unit.
All study participants provided written informed consent.
The study received ethical approval from the Malawi Ministry
of Health National Health Sciences Research Committee.
Analysis
The recorded IDIs and FGDs were simultaneously tran-
scribed and translated verbatim from Chichewa into English
by the RAs. Data were analyzed using thematic analysis [7].
A code list was generated by the principal investigator
and co-investigator based on the study objectives and
findings. Transcripts were uploaded into the qualitative
analysis software Maxqda version 10 (VERBI Software, Berlin,
Germany) and coded by three individuals. At three time
points throughout the coding process, transcripts were
compared and examined line by line to ensure consistency
in the application of codes between the different coders.
The code list was then updated and code definitions further
defined. Data were summarized through descriptive, text-
based summaries and data display matrices. In the data
matrices, data were separated by study populations and
compared for similarities and differences. The summaries and
data matrices helped to identify the overarching themes and
categories. Quotes were selected that were representative of
the main themes.
Results
Thirty-nine IDIs were conducted with women enrolled in the
Option B programme, including 19 pregnant women and
20 postpartum women. Sixteen FGDs were conducted; four
with HCWs, eight with postpartum women and four with
pregnant women. Across all groups, the majority had primary
education and were married. There were some differences in
age across the groups: the pregnant women in the IDIs were
older, with an average age of 31 to 35 years, whereas the
pregnant women in the FGDs were primarily aged 26 to 35
years. In the postpartum group, women tended to be slightly
younger, with those participating in the IDIs primarily aged
26 to 30 years old (Table 2). The majority of HCWs were
nurses with 1-10 years of experience and the greater
proportion were between the ages of 25-34 (Table 3).
Key study results are shown in Table 4.
Acceptability of the drug regimen used in Option B
Perception of drugs as health-enhancing
Women with prior receipt of antiretrovirals (ARVs) (e.g. for
PMTCT in prior pregnancies) reported having fewer side
effects and feeling healthier on Option B compared to
their previous drug regimens. Women also reported in-
creased appetite, weight gain and reduction in diarrhoea,
vomiting, body sores, sickness and headaches. A pregnant
woman stated, ‘‘I had some challenges with the old regimen
because I was feeling headaches for some time but with this
new regimen I am now okay.’’ Many women, both pregnant
and postpartum, expressed a positive attitude towards
Option B and discussed the importance of initiating ART
to feel healthier, to prolong their life and have a HIV-negative
child. ‘‘I was happy because I was told that I will be strong
and will live longer’’ (postpartum woman).
Normalization of appearance
Both pregnant and postpartum women discussed seeing
positive results in the community of women taking ART and
looking healthy. Some women discussed positive encourage-
ment from friends who were taking ART and were pleased
with the results:
When I faced the problem [HIV diagnosis] and I
asked other people, they said that, ‘‘aahh . . . we go
and receive medicine and do you see the way we
look right now.’’ And that’s how I also accepted that
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I, too, should be receiving medicine so that I should
look like my friends are looking. (Pregnant woman)
Women reported that identifying people who are HIV
positive is difficult because those on medication look healthy.
Some women reported that seeing these positive results in
others encouraged them to start Option B. A postpartum
woman commented, ‘‘. . . for me I feel that the drugs are
good because none can know that I am HIV positive.’’
Scepticism about lifelong treatment
One of the main adherence challenges was continuing on
ART after childbirth. The HCWs noted that many women did
not see the need to take ART after giving birth. HCWs
reported that some women asked if they were to stop taking
ART when they finished breastfeeding and restart ART when
they felt ill. The idea of continuing to take the medication
as a lifelong commitment regardless of their health condition
was a major concern to the both pregnant and postpartum
women. ‘‘I was worried because I was thinking of taking
drugs daily, [I] stopped [after] two weeks dosage . . . you
don’t feel like taking them any more . . . ’’ (postpartum
woman). Another woman reported that the counselling had
been sufficient but that she was ‘‘not ready to take the drugs
for my whole life’’ (postpartum woman).
Acceptability of PMTCT counselling services
ART initiation on the same day as HIV diagnosis
(same-day initiation)
All groups discussed the challenges of asking women to
initiate ART on the same day they learn their HIV status.
It’s hard to convince them that that very same day
they should start taking medicine and that when the
viral load is high you are most likely to transmit the
Table 2. Overview of pregnant and postpartum women







Pregnant women (four FGDs)
n19
n (%)




15 to 20 1 (5) 1 (5) 1 (5) 4 (5)
21 to 25 4 (21) 7 (35) 4 (21) 20 (27)
26 to 30 3 (16) 7 (35) 6 (32) 22 (30)
31 to 35 10 (53) 5 (25) 6 (32) 18 (24)
36 to 40 1 (5) 0 2 (11) 10 (14)




16 (84) 16 (80) 18 (95) 58 (78)
Single/divorced 3 (16) 4 (20) 1 (5) 16 (22)
Education
None 2 (11) 1 (5) 3 (16) 14 (19)
Primary 12 (63) 11 (55) 10 (53) 40 (54)
Secondary 5 (26) 7 (35) 6 (32) 19 (26)
Tertiary 0 1 (5) 0 0
Missing 0 0 0 1 (1)
FGD, focus group discussion.




25 to 29 10 (23)
30 to 34 9 (21)
35 to 39 8 (19)
40 to 44 7 (16)
46 9 (21)
Mean (sd) 38.1 (10.2)
Level of qualification
ART clerk 3 (7)
Nurse 27 (63)
Clinical officer 6 (14)
Health surveillance 4 (9)
Medical assistant 2 (5)
Counsellor 1 (2)
Years in current position
1 to 5 11 (26)
6 to 10 13 (30)
11 to 15 6 (14)
16 to 21 5 (12)
21 8 (19)
Mean (sd) 12.4 (10.4)
ART, antiretroviral therapy.
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Table 4. Key study findings
Acceptability of the drug regimen
Perception of drug as
health-enhancing
 Women reported feeling healthier on Option B. It has given me strength, not getting sick often.
Working like other people work and the body isn’t
weak. (Lactating woman)
 Women were motivated to initiate ART to regain their
own health.
Now I feel like my body is better than before because at
first my body was very weak and I wasn’t fat but I was




 Women reported seeing positive results in the
community, with sick women regaining their health.
They [the women] say that the drugs have brought
them back to their original shape because they are
looking nice now. (Pregnant woman)
 Women reported that the healthy appearance of
those on ART improved.
I thought that if these people are taking the medicine
and look like that, then why shouldn’t I? So I decided to
take the medicine. (Lactating woman)
Scepticism about lifelong
treatment
 Women struggled with the lifelong commitment to
drugs.
It was something difficult to accept because it was
something you weren’t expecting. You came here for
ANC, they’re testing your blood and they’re telling you
that today you have been found to be HIV and today
you will have to start taking medicine. It was
something that you weren’t thinking about and you
weren’t expecting, so it was something difficult to
accept, that ‘‘just today I should start taking medicine
and I’ll have to take the medicine for the rest of my
life.’’ (Pregnant woman)
Acceptability of the PMTCT counselling services
Inappropriate timing of ART
initiation
 HCWs and women expressed concerns about the
counselling provided.
The first counselling is not enough because it is not easy
for someone to have come to ANC, have her blood
tested, be found to be HIV positive and at the same time
be told to initiate to ART. As a result more women just
accept it to please us and [so we will] let them go, but
when they go home they don’t take the medicine or
disclose to their husbands. So the programme of Option
B is there but we don’t provide enough information to
women when they are to initiate ART, and it becomes a
problem for them to follow the procedure. (HCW)
 Women were uncomfortable initiating ART the same
day as learning their HIV status; they wanted to get
their husband’s permission first and receive a CD4
count before initiating ART.
The woman cannot even start taking the medicine
without the husband’s knowledge and that’s what
makes women who come alone not take the decision to
start taking the medicine. (HCW)
 HCWs and women reported not trusting the HIV test
result and wanting to obtain an additional HIV test at
a different facility for confirmation.
I doubted [the results] very much, so that I went to four
different hospitals, where I failed to get confirmation.
At first I went to two private clinics, then the third time
I went to Bottom Hospital, and the fourth time is when
I went to Kapiri, and that’s when I saw that these
things are actually true. (Pregnant woman)
Poor counselling
procedures
 HCWs and women stressed the importance of
adequate time being spent with the woman to
educate her about ART and how to take care of
herself.
It is because he didn’t have enough time to explain
what we are supposed to be doing; he seemed to be
rushing too when he was conducting his sessions, yet
we needed enough time to learn what we are
supposed to be doing. (Lactating woman)
 The most common recommendation was
strengthening and extending the counselling.
I would like the healthcare workers to have enough
time to counsel their clients so that the clients can
make good decisions. (Pregnant woman)
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virus to the child; they don’t really understand or
that they should accept it. A lot of people live in
denial. So it’s too hard that even if you initiate them
the same day at antenatal, it’s not like when they go
home they’ll take the medicine; it’s very difficult.
(HCW)
Women were also uncomfortable initiating ART on the
same day as learning their status, because they needed to get
their husband’s permission to initiate ART:
. . . here in Malawi most of the decision-making is
done by the husband and the husband has remained
behind and hasn’t come along to the hospital. It
becomes very difficult for the woman to make the
decision alone to start taking the medicine in the
absence of the husband. (HCW)
HCWs said it was more difficult for women to accept
Option B without having their CD4 count, because they
were familiar with the previous practice of testing the CD4
count to determine whether one should start ART. Some
HCWs reported that convincing women to accept ART with-
out a CD4 count was challenging. These women felt healthy
and were reluctant to start ART:
For me to accept that I should start taking the
medicine [was difficult] when I didn’t even know
what was my CD4 [count]. I was very argumentative.
In my heart I was still uncomfortable that they don’t
know what my CD4 count is, and should I start
taking medicine? (Pregnant woman)
Both pregnant and postpartum women reported feeling
uncomfortable initiating ART because they did not believe
the test result and wanted to get a second test (often at a
different facility) before initiating ART. One HCW stated,
‘‘They don’t believe in what they have been told, that they
are HIV positive, and they refuse to take the medication.’’
Some women reported being too distracted with news of
their HIV status to listen to or understand the counselling
messages.
Poor counselling services
In general, both the pregnant and postpartum women felt
that the HCWs were kind, friendly and supportive. However,
both groups and the HCWs expressed concern about the
counselling services, and the women felt that the way Option
B was introduced was very important. The majority
of women stressed the importance for HCWs to exercise
patience and understanding when initiating a woman to
Option B, since this was crucial to acceptance and
adherence of lifelong ART.
HCWs also agreed that it is very important for counselling
to be thorough at the introduction of Option B and for the
woman to be educated about ARVs so that she can make an
informed decision:
Women can be advised that ARVs are not drugs for
trial [to try]. When making a decision the person
should know that it will be lifelong treatment. At the
same time we need to highlight the challenges they
will face when taking the drugs. Now if she under-
stands, she will not get surprised if she [encounters]
a problem; she will know that this is what the doctor
said. (HCW)
Despite most women agreeing to start treatment, the
HCWs worried that some women would not take the
medication after leaving the facility:
The first counselling is not enough because it is not
easy for someone to have come to ANC, have their
blood tested, be found to be HIV positive, and at the
same time be told to initiate ART. As a result more
women just accept it to please us and [so we will] let
them go, but when they go home they don’t take
the medicine and disclose to their husband. So the
programme of Option B is there, but we don’t
provide enough information to women [about]
when they are to initiate ART, and it becomes a
problem for them to follow the procedure. (HCW)
The most common recommendation discussed by preg-
nant and postpartum women was strengthening and extend-
ing counselling. Some pregnant women reported that they
were only given the drugs and told how to take them but not
provided proper counselling. Some lactating women even
claimed that they did not receive any counselling nor were
they given any opportunity to ask questions, but were just
given an appointment date to collect medicine. A pregnant
Table 4 (Continued )
Acceptability of the drug regimen
Loss to follow-up  HCWs discussed women not returning to the facility
after initiation and the challenges of dealing with
women who are lost to follow-up.
Many clients are initiated on ART but a lot of them,
when they go home and come back here, you’ll find
that they tell you that, ‘‘I haven’t started taking the
medicine,’’ or that, ‘‘I started taking them rather late
and I’ve stopped taking them because of this and that
reason,’’ and they are not coming back. (HCW)
They come because of the pregnancy, but when [the
baby] is delivered maybe we will not see her. (HCW)
ANC, antenatal clinic; ART, antiretroviral treatment; HCW, healthcare worker; PMTCT, prevention of mother-to-child transmission.
Katirayi L et al. Journal of the International AIDS Society 2016, 19:20919
http://www.jiasociety.org/index.php/jias/article/view/20919 | http://dx.doi.org/10.7448/IAS.19.1.20919
6
woman explained, ‘‘I would like the HCWs to have enough
time in counselling their clients so that the clients can be
making good decisions.’’
HCWs discussed how difficult it is to get some of the
women to return to the facility to receive additional in-
formation on Option B. The majority of the women
reported they only received counselling once or twice,
usually when they went for their initial HIV testing. A HCW
stated, ‘‘. . . most of the time the clients [on Option B] are
on medication, yet they don’t have detailed information on
ARVs.’’
Some postpartum women stated that they were able to
get more comprehensive counselling when the HCWs visited
them at their homes; however, women are provided with this
option at some facilities and are free to decline. ‘‘When they
[HCWs] started following me to my home . . . for further
counselling, [that] is when I started getting good information
about the ART’’ (postpartum woman). Both pregnant and
postpartum women had many unanswered questions about
Option B, including taking it with other drugs, conse-
quences of missing a pill, what to do if they did not plan to
have more children and other topics.
Loss to follow-up
HCWs reported that some women did not return to the
facility for counselling after receiving the first bottle of
drugs and that the facilities were not able to track or retain
women who were LTFU due to lack of transport, incentives
for personnel and disclosure challenges. They were con-
cerned that those who are LTFU will increase the number of
people resistant to ART:
. . . many clients are initiating on ART but a lot of
them when they go home and come back here,
you’ll find that they tell you that, ‘‘I haven’t started
taking the medicine’’ or that, ‘‘I started taking them
rather late and I’ve stopped taking them because of
this and that reason,’’ and they are not coming back.
So we could have this problem in future whereby
such people could develop resistance and for them
to restart the medicine, they may not work properly.
(HCW)
Discussion
This study’s results highlight the generally positive perception
towards the drug regimen used in Option B; women who
had received ARVs for PMTCT in prior pregnancies experi-
enced fewer side effects and women generally recognized
the positive benefits of ART on their health. Women felt
hopeful about prolonging their life and having an HIV-
uninfected baby, yet still grappled with the fact that ART is
a lifelong commitment. Many women struggled with initiat-
ing ART on the same day as learning their HIV status. Women
wanted to discuss with their husbands first, receive a CD4
count and receive an HIV test at another facility to confirm
their HIV status. HCWs expressed concern that women may
just agree to take the drugs and then do as they please once
they leave the facility. HCWs discussed concerns about
women being LTFU and developing resistance.
Seeing the positive results of others encouraged women to
initiate ART, and women emphasized the importance of
restoring their health to return to their daily activities.
The association of ART as ‘‘health enhancing’’ is a shift from
the previous perception of ART being a sign of health
deterioration. ART was previously seen as something that
very ‘‘ill’’ patients living with HIV had to receive [8]. It is
interesting to note that women discussed their own health
more frequently than preventing transmission of HIV to their
infant. The ‘‘normalization’’ of appearance is also a shift, as
previous studies have documented ART, particularly when
stavudine was a regimen component, being associated with a
‘‘deterioration’’ of appearance [9].
Our study also highlighted women’s concern about com-
mitment to lifelong treatment, which has also been documen-
ted in the literature [10]. This is an interesting contradiction
expressed by the women in our findings, as women frequently
mentioned the benefits of taking Option B for their own
health benefits and yet discussed discontinuing ART after
delivery or breastfeeding. This could be tied to the perception
of ART being health enhancing and women believing they can
take ART, recover their health and then stop taking ART.
Previous literature on short-course prophylaxis has docu-
mented similar feelings of hopelessness, shock and blaming
oneself; however after the initial phase women seemed to
accept their situation [11]. These results differed from our
study findings, which did not find that acceptance increased
after the initial phase.
One study in Malawi found that while time to ART ini-
tiation was significantly shorter, LTFU on ART increased from
5.8 to 11.2% after the introduction of Option B [12].
Higher attrition has been observed when women initiate ART
to PMTCT during pregnancy compared with those who
initiate for their own health [4]. Our study identified two
main challenges to women accepting lifelong ART: the
practice of initiating women on ART the same day they learn
their HIV status and insufficient counselling to understand
ART and the lifelong commitment of ART. Previous research
has highlighted the challenges of same-day initiation of ART.
A study on Option B in Malawi found that those who
started ART on the day of HIV testing were almost twice as
likely never to return to the clinic (adjusted OR 1.9; 95% CI
1.5 to 2.4) than Option B patients who started ART later
(pB0.001) [4]. Our study findings show that women want
more time to speak with their partner before initiating ART.
Many women were surprised by their HIV diagnosis, ques-
tioned their test results and sought additional HIV testing
elsewhere. Additionally, as CD4 count is perceived to be a
main factor in determining whether treatment is necessary,
many women found it difficult to accept initiating ART with-
out it [13]. Additional counselling messages may need to be
developed to explain why a CD4 count to establish ART
eligibility is no longer required.
Our study found that some women felt that not enough
time was available for counselling and encouraged a more
thorough introduction to lifelong ART. It is interesting to note
that similar findings were experienced with short-course
ARV prophylaxis regarding service delivery. One systematic
review found that the most common service delivery factors
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associated with low adherence included quality and timing
of HIV testing and counselling; lack of emphasis of the
importance of ARV adherence at post-counselling and follow-
up care; and lack of male involvement, such as asking the
partner to be tested or couples’ counselling. These service
delivery challenges are similar to the concerns experienced
under Option B [14]. HCWs expressed concern that
women were not receiving adequate information. A study
on Option B in Malawi found that facilities that offered
additional adherence counselling beyond the required na-
tional guidelines had lower rates of early LTFU [4]. Other
research articles have proposed evaluating new counselling
models, such as sequenced counselling messages that first
introduce ART as a PMTCT tool to protect the child and then
introduce the benefits of lifelong ART and prepare women for
long-term adherence and retention [15].
There are limitations to this study. The study population
has limitations, as it only included women who accessed the
health facility, initiated ART, had a live child and breastfed
their child. This population does not include more vulnerable
populations who may not have access to a facility, rejected
Option B, whose child did not live or who were unable to
breastfeed their child. Participants were 18 years of age and
older; thus the views of younger women have not been
explored.
Conclusions
Although Option B has significantly increased the number
of women initiating ART, there are still challenges that need
to be addressed to strengthen initiation, adherence and
retention in the Option B programme; same-day ART
initiation stands out as particularly challenging. Strategies
to strengthen the counselling services at initiation need to
be developed to improve same-day ART initiation and long-
term ART adherence. More research evaluating different
counselling models and messages for same-day initiation
ART is needed. These are important lessons learned for
Malawi and other countries implementing Option B as
they further develop counselling messages and patient
education services.
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